The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."
Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan
Testing will be reimbursed for patients with early-stage breast cancer to guide adjuvant treatment with the PARP inhibitor Lynparza.
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
OIG Continues Crackdown on Genetic Testing Fraud as Medicare Spending Spikes
Amid increasing spending on genetic testing, there are more opportunities for bad actors to implement interstate, fraudulent billing schemes, according to OIG.
Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes
The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care.